Are seaweed-controlled oral cell therapies the future of inflammatory bowel disease (IBD) therapy? That is the question posed by the latest deal from Genentech, which is teaming up with Novome Biotechnologies to study a novel approach to the indication.
The deal sees Genentech pay $15 million upfront and commit up to $590 million in milestones for the chance to work with Novome on a multitarget IBD collaboration. Novome will handle research up to the start of IND-enabling studies, with Genentech handling clinical trials and commercialization of any candidates that make it that far.
